74 results
Keyword Inflectra Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Inflectra
infliximab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 10/09/2013,
, Revision: 29, Authorised, Last updated: 12/05/2022
Inflectra Musculoskeletal Diseases Joint … Inflectra … Inflectra, infliximab 7 Westferry … -
List item
Direct healthcare professional communication (DHPC): Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use of live vaccines in infants exposed in utero or during breastfeeding
Active substance: infliximab, DHPC type: New contraindication, Last updated: 07/03/2022fliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … fliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … -
List item
Human medicine European public assessment report (EPAR): Zessly
infliximab, Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Rheumatoid; Colitis, Ulcerative; Spondylitis, Ankylosing
Date of authorisation: 18/05/2018,, Revision: 10, Authorised, Last updated: 12/12/2022
Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … -
List item
Human medicine European public assessment report (EPAR): Remicade
infliximab, Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis; Crohn Disease; Arthritis, Psoriatic; Colitis, Ulcerative
Date of authorisation: 13/08/1999, Revision: 61, Authorised, Last updated: 26/09/2022fliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … -
List item
Press release: European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars
CHMP, Last updated: 28/06/2013biosimilars. Remsima and Inflectra both contain the same known … Union since 1999. Remsima and Inflectra are recommended for authorisation … CHMP opinions on Remsima and Inflectra will now be sent to the European … -
List item
Human medicine European public assessment report (EPAR): Remsima (updated)
infliximab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 10/09/2013,, Revision: 34, Authorised, Last updated: 17/05/2023
Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … -
List item
Human medicine European public assessment report (EPAR): Flixabi
infliximab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid; Crohn Disease; Psoriasis
Date of authorisation: 26/05/2016,, Revision: 23, Authorised, Last updated: 06/02/2023
Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013
CHMP, Last updated: 28/06/2013Inflectra … -
List item
Human medicine European public assessment report (EPAR): Blitzima
rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017,, Revision: 18, Authorised, Last updated: 02/02/2023
-
List item
Human medicine European public assessment report (EPAR): Truxima
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Wegener Granulomatosis; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopic Polyangiitis
Date of authorisation: 17/02/2017,, Revision: 19, Authorised, Last updated: 31/01/2023
-
List item
Human medicine European public assessment report (EPAR): Ritemvia
rituximab, Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Wegener Granulomatosis
Date of authorisation: 13/07/2017,
, , Revision: 8, Withdrawn, Last updated: 16/08/2021
-
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 April 2023
European Medicines Agency, Amsterdam, the Netherlands, from 11/04/2023 to 14/04/2023, Last updated: 11/04/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/05/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/03/2022 to 10/03/2022, Last updated: 22/11/2022 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 22/05/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 11/10/2021 to 14/10/2021, Last updated: 20/01/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 November 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/11/2022 to 10/11/2022, Last updated: 10/01/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 July 2020
European Medicines Agency, Amsterdam, the Netherlands, from 06/07/2020 to 09/07/2020, Last updated: 10/12/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 16/03/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 September 2015
European Medicines Agency, London, UK, from 07/09/2015 to 10/09/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 September 2018
European Medicines Agency, London, UK, from 03/09/2018 to 06/09/2018, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 September 2016
European Medicines Agency, London, UK, from 26/09/2016 to 29/09/2016, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 30 November-3 December 2015
European Medicines Agency, London, UK, from 30/11/2015 to 03/12/2015, Last updated: 13/03/201415 4.1.4. Infliximab – INFLECTRA (CAP), REMICADE (CAP), REMSIMA … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 August-1 September 2017
European Medicines Agency, London, UK, from 29/08/2017 to 01/09/2017, Last updated: 13/03/2014